Sumitomo Dainippon Pharma Annual Report 2017
22/102

Taking on the challenge to discover new, fundamental treatments for neurodegenerative disorders, at the intersection of psychiatric and neurologic researchThe Psychiatry & Neurology area is one in which Sumitomo Dainippon Pharma has had longstanding expertise, with eight products/compounds launched in the last quarter of century since the 1990s. We are making progress in research and development aiming to discover fundamental disease modifying drugs in neurodegenerative disorders which could improve motor activities and cognitive functions.Furthermore, with regard to psychiatric disorders, we have directed resources to diseases and symptoms insufficiently treated by current regimens, and will expand our focus of drug discovery to “treatment-resistant depression and schizophrenia” and “symptoms associated with neurodegenerative disorders”. The latter includes behavioral and psychological symptoms of dementia (BPSD), and Parkinson disease with psychosis (PDP). This can also be described as the merging of research on psychiatric and neurodegenerative disorders. At present, we have multiple compounds at the stage of clinical development targeting BPSD and PDP.Exercising unique research methodsWe are dedicating efforts to utilize our unique phenotypic drug screening systems to produce original drug candidates. Using characteristic cells grown from iPS cells derived from patients with various diseases, we are measuring phenotypic readouts possibly related to clinical symptoms.Psychiatry & Neurology AreaIn the Oncology area, we are committed to contribute to treatments for patients with cancer, and are driving research and development forward under the four core strategies below. Our aim is to deliver unique products that have not been available to date.• Cancer Stemness Inhibitor• Cancer Peptide Vaccine• Kinase Inhibitor• aiRNA therapeuticWe are aiming for a fiscal 2019 launch of the cyclin-dependent kinase (CDK) 9 inhibitor alvocidib. Additionally, we are making progress with development of the cancer stemness inhibitor napabucasin and cancer peptide vaccine DSP-7888 as we steadily push forward R&D aiming for on-going approvals and product launches in the Oncology area.Newly acquired Tolero Pharmaceuticals is utilizing evaluation systems that assess disease relevance and in-silico drug discovery platforms, while striving to discover drugs targeting kinases that are highly related to diseases.Oncology AreaDrug DiscoveryResearch Strategies in the Psychiatry & Neurology AreaResearch Strategies in the Oncology AreaNeurologySchizophreniaAutismDepressionAnxietyCancer StemnessInhibitorNapabucasin AmcasertibBBI-801a (preclinical)DSP-7888AmcasertibAlvocidibTP-0903TP-1287 (preclinical)TP-0184 (preclinical)aiRNAtherapeuticCancer PeptideVaccineKinaseInhibitorBehavioral andPsychologicalSymptoms ofDementia (BPSD)Parkinson’s DiseasePsychosis (PDP)etc.Alzheimer’sdisease (AD)Dementia withLewy Bodies(DLB)AmyotrophicLateral Sclerosis(ALS)Parkinson’sdisease (PD)PsychiatrySolid tumorsHematologicmalignanciesResearch & Development21Sumitomo Dainippon Pharma Co., Ltd. Annual Report 2017

元のページ  ../index.html#22

このブックを見る